Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Denali Therapeutics Inc.

    NASDAQ: DNLI · Real-Time Price · USD
    14.10
    -0.39 (-2.69%)
    At close: Jun 27, 2025, 2:40 PM

    Denali Therapeutics Statistics

    Share Statistics

    Denali Therapeutics has 145.28M shares outstanding. The number of shares has increased by 1.83% in one year.

    Shares Outstanding

    n/a
    		 145.28M

    Shares Change (YoY)

    n/a
    		 1.83%

    Shares Change (QoQ)

    n/a
    		 0.9%

    Owned by Institutions (%)

    n/a
    		 75.51%

    Shares Floating

    n/a
    		 125.73M

    Failed to Deliver (FTD) Shares

    n/a
    		 163,877

    FTD / Avg. Volume

    n/a
    		 10.44%

    Short Selling Information

    The latest short interest is 12.22M, so 8.41% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 12.22M

    Short % of Shares Out

    n/a
    		 8.41%

    Short % of Float

    n/a
    		 9.42%

    Short Ratio (days to cover)

    n/a
    		 9.75

    Valuation Ratios

    The PE ratio is -7.93 and the forward PE ratio is -5.3. Denali Therapeutics's PEG ratio is -0.06.

    PE Ratio

    n/a
    		 -7.93

    Forward PE

    n/a
    		 -5.3

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 2.9

    PB Ratio

    n/a
    		 2.73

    P/FCF Ratio

    n/a
    		 -9.22

    PEG Ratio

    n/a
    		 -0.06
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Denali Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 8.46

    Quick Ratio

    n/a
    		 8.46

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -0.12

    Debt / FCF

    n/a
    		 -0.13

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-954,340.86

    Employee Count

    n/a
    		 443

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 68K

    Effective Tax Rate

    n/a
    		 -0.02%

    Stock Price Statistics

    The stock price has increased by -36.92% in the last 52 weeks. The beta is 1.33, so Denali Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.33

    52-Week Price Change

    n/a
    		 -36.92%

    50-Day Moving Average

    n/a
    		 14.39

    200-Day Moving Average

    n/a
    		 20.51

    Relative Strength Index (RSI)

    n/a
    		 52.4

    Average Volume (20 Days)

    n/a
    		 1,569,666

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -487.34M

    Net Income

    n/a
    		 -422.77M

    EBITDA

    n/a
    		 -414.91M

    EBIT

    n/a
    		 -422.7M

    Earnings Per Share (EPS)

    n/a
    		 -2.57
    Full Income Statement

    Balance Sheet

    The company has 174.96M in cash and 48.71M in debt, giving a net cash position of 126.25M.

    Cash & Cash Equivalents

    n/a
    		 174.96M

    Total Debt

    n/a
    		 48.71M

    Net Cash

    n/a
    		 126.25M

    Retained Earnings

    n/a
    		 -1.54B

    Total Assets

    n/a
    		 1.27B

    Working Capital

    n/a
    		 786.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -347.69M and capital expenditures -15.91M, giving a free cash flow of -363.61M.

    Operating Cash Flow

    n/a
    		 -347.69M

    Capital Expenditures

    n/a
    		 -15.91M

    Free Cash Flow

    n/a
    		 -363.61M

    FCF Per Share

    n/a
    		 -2.21
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    DNLI does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for DNLI is $32.5, which is 124.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $32.5

    Price Target Difference

    n/a
    		 124.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 16
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 5.21

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist